According to our recent payer coverage analysis for breast cancer (HER2+) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for breast cancer (HER2+) treatments shows that under the pharmacy benefit, about 32% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In July 2019, Amgen Inc. and Allergan plc launched oncology drugs Mvasi
(bevacizumab-awwb), an Avastin (bevacizumab) biosimilar, and Kanjinti (trastuzumab), a Herceptin (trastuzumab) biosimilar.
To read the full Reality Check on Breast Cancer (HER2+) treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: